Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935025 · ClinicalTrials.gov registry record · Phase 1
AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00935025 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT00935025, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a phase I, single-blind, randomized, placebo-controlled single and repeated ascending dose study to assess the safety, tolerability and pharmacokinetics with oral doses of AZD1305 extended-release capsules in healthy male Japanese and Caucasian subjects. Three (or four if needed) dose levels will be given to Japanese subjects and one of the doses will also be given to Caucasian subjects.
Interventions
- DRUG Placebo
- DRUG AZD1305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935025
The ClinicalTrials.gov registry entry for NCT00935025 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00935025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935025 about?
NCT00935025 is a clinical study titled "AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects". This is a phase I, single-blind, randomized, placebo-controlled single and repeated ascending dose study to assess the safety, tolerability and pharmacokinetics with oral doses of AZD1305 extended-release capsules in healthy male Japanese and Caucasian subjects. Three (or four if needed) dose levels...
What is the current status of trial NCT00935025?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2009-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00935025?
The interventions under investigation include: Placebo (DRUG), AZD1305 (DRUG).
Who is sponsoring clinical trial NCT00935025?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.